drugset
drugset / Trial / NCT04844463

A Study of JNJ-68179280 in Healthy Participants

NCT04844463 ↗

Phase 1 Completed 94 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to evaluate the safety and tolerability of JNJ-68179280 compared with placebo after administration of single ascending oral doses of JNJ-68179280 administered to healthy participants (Part 1), multiple ascending oral doses of JNJ-68179280, administered to healthy participants once daily (Cohorts 1 through 4) or twice daily (Cohort 5) over 14 consecutive days (Part 2) and multiple ascending oral doses of an alternative JNJ-68179280 formulation, administered to healthy participants once daily over 14 consecutive days (Part 3 if conducted).

Timeline

Start
2021-05-26
Primary completion
2023-03-07
Completion
2023-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-68179280 Unknown — Oral

Indications

No indication recorded.